Innovative Products Continued to Deliver and Perform Excellently Revenue Recorded RMB26.20 Billion Adjusted non-HKFRS Profit Attributable to the Owners of…
Browsing: Sino Biopharmaceutical Limited
Steadily Advances Innovation and R&D Revenue Climbs to RMB15.28 Billion Adjusted Non-HKFRS Profit Attributable to the Owners of the Parent…
Revenue Up by 7.1% to RMB28.78 Billion Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Up by 16.4%…
Contribution of Sales of New Products to Revenue Rises to 47.4% Driving Revenue Up by 16.4% Sino Biopharmaceutical Limited (Sino…
By Accelerating New Drug Development and Employing New Online Platforms Sales of New Drugs Marketed over Past Three Years Double…
Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Group”; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life…
Revenue Increases by 1.0% to RMB12.648 Billion Underlying Profit up 5.2% to RMB1.761 Billion Sino Biopharmaceutical Limited (“Sino Biopharm” or…
Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading and innovation-driven pharmaceutical…
Revenue Up 33.4% to RMB6,208 Million Underlying Profit* Climbs 22.4% to RMB976 Million Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the…
Revenue Up 41% to RMB20.9 Billion and Net Profit Climbs 317% to RMB9 Billion HONG KONG – (ACN Newswire) – Sino Biopharmaceutical Limited…